8月21日，Hims & Hers Health盘中上涨5.16%，报33.52美元/股，成交额1.21亿美元。
消息面上，公司CEO Andrew Dudum近日公开接受媒体采访，就FTC指控公司向Meta及Snap共享用户健康数据、收费违规及订阅取消障碍等问题进行正面回应，强调相关指控源于对公司商业模式的误解，公司是"积极的颠覆者"。管理层连续积极表态持续缓解市场担忧，叠加Needham上调目标价至42美元、Morgan Stanley上调目标价至28美元等利好信号，推动股价延续反弹走势。自7月30日FTC诉讼公布当日暴跌逾12%以来，HIMS已实现连续多日回升。
Hims & Hers Health Inc是一家多专业远程医疗平台，将消费者与持牌医疗保健专业人员联系起来，使他们能够获得与心理健康、性健康、皮肤病学、头发护理等相关的多种疾病的高质量医疗服务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.